Obesity is a chronic disease defined by excess body fat that damages health. It affects over 42% of American adults according to CDC data from 2023, and that number has roughly tripled since 1980. This guide covers everything you need to know about obesity: how it’s diagnosed, what it does to your body, and every treatment option available in 2026, from dietary changes to GLP-1 medications to bariatric surgery.<\/p>\n
If you’re reading this because you think you might have obesity, or because a doctor told you that you do, the single most useful thing to know is this: obesity responds to treatment. It’s not a character flaw. The biology is well understood now, and the treatment options are better than they’ve ever been.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey, and you can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Obesity is diagnosed when a person’s body mass index (BMI) reaches 30 or higher, indicating excess body fat that increases disease risk.<\/strong> BMI is calculated by dividing weight in kilograms by height in meters squared. While BMI isn’t perfect, it remains the standard screening tool used in clinical practice worldwide.<\/p>\n Quick Answer: Over 42% of U.S. adults have obesity, a rate that has roughly tripled since 1980.<\/p>\n The World Health Organization and the CDC both use these BMI categories:<\/p>\n Some clinicians now add waist circumference measurements. A waist over 40 inches in men or 35 inches in women signals abdominal obesity even when BMI is borderline. The 2023 American Association of Clinical Endocrinology (AACE) guidelines also recommend looking at actual health complications rather than relying on BMI alone.<\/p>\n BMI has real limitations. It doesn’t distinguish between muscle mass and fat mass. A bodybuilder with 8% body fat can technically qualify as “obese” by BMI. It also doesn’t capture where fat is stored, which matters a lot. Visceral fat around the organs is far more dangerous than subcutaneous fat under the skin.<\/p>\n That said, for the vast majority of people, BMI correlates well enough with health outcomes to be clinically useful. The National Heart, Lung, and Blood Institute (NHLBI) reviewed decades of evidence and concluded BMI remains a reasonable first-pass screening tool when combined with clinical judgment.<\/p>\n Over 42% of U.S. adults had obesity as of the 2017-2020 NHANES data cycle, and severe obesity (BMI 40+) affected 9.2%. The problem has gotten steadily worse for decades. In 1990, no state had an obesity rate above 15%. By 2022, every state exceeded 20%, and 23 states were above 35%.<\/p>\n The numbers aren’t evenly distributed. Obesity rates are higher among Black adults (49.9%) and Hispanic adults (45.6%) compared to white adults (41.4%) and Asian adults (16.1%), per CDC 2020 data. Income and geography matter too. Rural counties have obesity rates roughly 6 percentage points higher than urban areas. States in the South and Midwest consistently report the highest rates.<\/p>\n Childhood obesity has also climbed. About 19.7% of children and adolescents aged 2 to 19 had obesity in 2017-2020, according to the CDC. That’s roughly 14.7 million kids.<\/p>\n The economic toll is staggering. A 2021 study published in the Journal of Obesity estimated that obesity-related medical costs in the U.S. reached $173 billion per year. People with obesity spend approximately $1,861 more per year in medical costs than people at normal weight.<\/p>\n Obesity results from a sustained energy imbalance where calorie intake exceeds expenditure, but the reasons behind that imbalance are far more complex than “eating too much.” Genetics, hormones, environment, medications, sleep, stress, and socioeconomic factors all play roles.<\/strong><\/p>\n Twin studies have consistently shown that BMI is 40-70% heritable. The FTO gene, identified in 2007, was the first common obesity gene discovered, and since then genome-wide association studies (GWAS) have identified over 900 genetic loci linked to BMI. Most of these individually contribute tiny effects, but they add up.<\/p>\n Rare single-gene mutations can cause severe early-onset obesity. Mutations in the MC4R gene, for instance, are found in about 5-6% of people with severe childhood obesity. Leptin deficiency, while extremely rare, causes insatiable hunger from birth.<\/p>\n The hypothalamus regulates appetite through a system involving leptin, ghrelin, insulin, GLP-1, and dozens of other signaling molecules. When someone loses weight, the body fights back. Leptin drops, ghrelin rises, metabolic rate decreases, and appetite increases. This isn’t weakness. It’s physiology.<\/p>\n A landmark 2011 study by Sumithran et al. in the New England Journal of Medicine showed that these hormonal changes persist for at least 12 months after weight loss, which explains why people regain weight so consistently after dieting.<\/p>\n The modern food environment makes overeating easy. Ultra-processed foods, which the NOVA classification system defines as industrial formulations with five or more ingredients, now account for about 58% of calories consumed by U.S. adults, according to a 2024 analysis of NHANES data published in The BMJ.<\/p>\n A 2019 randomized controlled trial by Kevin Hall at the NIH directly tested what happens when you feed people ultra-processed vs. unprocessed diets for two weeks. On the ultra-processed diet, people ate about 500 more calories per day and gained weight. On the unprocessed diet, they lost weight. The meals were matched for calories, sugar, fat, and fiber made available, but people just ate more of the processed food.<\/p>\n Plenty of commonly prescribed medications cause weight gain: certain antidepressants (paroxetine, mirtazapine), antipsychotics (olanzapine, quetiapine), beta-blockers, insulin, sulfonylureas, and corticosteroids. A person gaining 20-30 pounds on olanzapine isn’t imagining things. The drug genuinely changes appetite signaling and metabolic function.<\/p>\n Short sleep duration (under 6 hours) is consistently associated with higher obesity risk. A meta-analysis by Cappuccio et al. (2008) in the journal Sleep found that short sleepers had a 55% higher risk of obesity. Cortisol from chronic stress promotes visceral fat deposition and increases cravings for calorie-dense food.<\/p>\n Obesity increases the risk of at least 13 types of cancer, type 2 diabetes, heart disease, stroke, sleep apnea, osteoarthritis, fatty liver disease, kidney disease, and depression.<\/strong> The relationship between obesity and early death is well-documented, though the curve isn’t perfectly linear.<\/p>\n Obesity is the single strongest risk factor for type 2 diabetes. About 80-90% of people with type 2 diabetes have overweight or obesity. The Diabetes Prevention Program (DPP) trial, published in 2002, showed that losing just 7% of body weight cut diabetes risk by 58% in high-risk adults. That’s a person weighing 250 pounds losing 17.5 pounds.<\/p>\n The Framingham Heart Study, running since 1948, showed that obesity doubles the risk of heart failure. The SELECT trial, published in 2023, demonstrated that semaglutide 2.4 mg reduced major cardiovascular events by 20% in people with obesity who didn’t have diabetes. That was the first time an anti-obesity medication showed direct cardiovascular benefit.<\/p>\n The International Agency for Research on Cancer (IARC) identified 13 cancers linked to obesity: esophageal, gastric, colorectal, liver, gallbladder, pancreatic, breast (postmenopausal), uterine, ovarian, kidney, meningioma, thyroid, and multiple myeloma. A 2019 study in The Lancet estimated that excess body weight accounted for about 4% of all cancers worldwide.<\/p>\n About 70% of people with obstructive sleep apnea have obesity, and the prevalence of sleep apnea increases sharply with rising BMI. The Wisconsin Sleep Cohort Study found that a 10% weight gain predicted a 32% increase in the apnea-hypopnea index and a 6-fold increase in the odds of developing moderate-to-severe sleep apnea.<\/p>\n The relationship between obesity and depression runs both ways. A 2010 meta-analysis by Luppino et al. in the Archives of General Psychiatry found that people with obesity had a 55% increased risk of developing depression, and people with depression had a 58% increased risk of becoming obese. Stigma, reduced mobility, chronic pain, and inflammatory markers all likely contribute.<\/p>\n Every pound of body weight puts about 4 pounds of pressure on the knee joints during walking. The Osteoarthritis Initiative found that people with obesity class II or III were more than 4 times as likely to need a knee replacement compared to people at normal weight. Weight loss of just 10% can significantly reduce knee pain and improve function.<\/p>\n Treatment for obesity falls into three categories: lifestyle modification (diet and exercise), medication, and surgery.<\/strong> The best approach depends on your BMI, your health conditions, how much weight you need to lose, and what you’ve already tried.<\/p>\n Every obesity treatment plan starts here. The evidence base for dietary change and physical activity is solid, though the long-term results of lifestyle-only approaches are modest.<\/p>\n The Look AHEAD trial, one of the largest lifestyle intervention studies ever conducted, followed over 5,000 adults with type 2 diabetes and obesity for up to 13.5 years. The intensive lifestyle intervention group lost an average of 8.6% of body weight in the first year. By year 8, that average had dropped to 4.7%. Better than nothing, but for someone with a BMI of 40, a 4.7% loss might mean going from 280 to 267 pounds. That’s meaningful for health markers but doesn’t resolve obesity.<\/p>\n The practical takeaway: lifestyle changes work best as a foundation. They improve cardiovascular fitness, preserve muscle mass, and enhance mental health regardless of how much weight they produce on the scale.<\/p>\n For specific diet and exercise guidance, see our obesity diet strategies<\/a> and exercise protocols<\/a> articles.<\/p>\n This is where the field has changed the most in the past five years. GLP-1 receptor agonists have transformed obesity treatment from a frustrating exercise in willpower to a manageable chronic disease treatment.<\/p>\n Semaglutide (Wegovy\u00ae):<\/strong> FDA-approved for obesity in June 2021. The STEP 1 trial showed an average weight loss of 14.9% over 68 weeks, compared to 2.4% for placebo. That’s the kind of result that was previously only achievable with surgery.<\/p>\n Tirzepatide (Zepbound\u00ae):<\/strong> FDA-approved for obesity in November 2023. This dual GIP\/GLP-1 receptor agonist produced even more impressive results. The SURMOUNT-1 trial reported average weight loss of 20.9% at the highest dose (15 mg) over 72 weeks. About 36% of participants on that dose lost more than 25% of their body weight.<\/p>\n Liraglutide (Saxenda\u00ae):<\/strong> The older GLP-1 option, FDA-approved in 2014. The SCALE Obesity and Prediabetes trial showed average weight loss of about 8% over 56 weeks. It’s less effective than semaglutide or tirzepatide but still a reasonable option for some patients.<\/p>\n Other options:<\/strong> Phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat (Xenical\/Alli) are also FDA-approved for obesity. They produce more modest weight loss, typically 5-10%, but can be useful alternatives when GLP-1 medications aren’t suitable.<\/p>\n For a deep dive into GLP-1 mechanism of action and clinical trial data, see our GLP-1 treatment guide<\/a>.<\/p>\n Surgery remains the most effective treatment for severe obesity by total weight lost. The three main procedures are:<\/p>\n Roux-en-Y gastric bypass:<\/strong> Average excess weight loss of about 60-70%. The stomach is reduced to a small pouch and connected directly to the mid-small intestine, bypassing most of the stomach and the duodenum.<\/p>\n Sleeve gastrectomy:<\/strong> Now the most commonly performed bariatric procedure in the U.S. Average excess weight loss of about 50-60%. About 80% of the stomach is removed, leaving a banana-shaped tube.<\/p>\n Adjustable gastric band (Lap-Band):<\/strong> Much less common now due to high complication and reoperation rates. Average excess weight loss of about 40-50%.<\/p>\n The Swedish Obese Subjects (SOS) study, a landmark prospective trial that followed bariatric surgery patients for up to 20 years, found that surgery reduced overall mortality by 29%, diabetes incidence by 78%, and cardiovascular events by 33% compared to matched controls who received conventional treatment.<\/p>\n Surgery has real risks though. Complication rates for sleeve gastrectomy run about 2-5%, and gastric bypass about 3-7%. Nutritional deficiencies are common long-term. About 20-25% of patients regain significant weight within 10 years.<\/p>\n For a detailed comparison of all three treatment approaches, see our treatment options comparison<\/a>.<\/p>\n GLP-1 receptor agonists reduce appetite by acting on GLP-1 receptors in the brain’s appetite centers, particularly the hypothalamus and brainstem.<\/strong> They slow gastric emptying, making you feel full longer. They also appear to reduce food reward signaling, meaning high-calorie foods become less appealing.<\/p>\n The natural hormone GLP-1 (glucagon-like peptide-1) is released by your gut after eating. It tells your pancreas to release insulin and tells your brain you’ve eaten enough. But natural GLP-1 breaks down within minutes. Semaglutide has been engineered to last about a week, which is why it’s a once-weekly injection.<\/p>\n Tirzepatide goes further by targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual mechanism appears to produce greater weight loss, though researchers are still working out exactly why GIP agonism adds benefit.<\/p>\n These medications don’t work by causing malabsorption or burning extra calories. They work by changing the signals your brain receives about hunger and satiety. For many patients, the experience is described as the constant background noise of food thoughts going quiet.<\/p>\n The main side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually worst during dose escalation and often improve over 4-8 weeks. Starting at a low dose and titrating up slowly helps. About 5-10% of patients in clinical trials discontinued due to GI side effects.<\/p>\n Key Takeaway: Losing just 5-10% of body weight measurably improves blood pressure, blood sugar, and joint pain.<\/p>\n Anyone with a BMI of 30 or higher should consider treatment.<\/strong> People with a BMI of 27 or higher plus at least one weight-related condition (type 2 diabetes, high blood pressure, high cholesterol, sleep apnea) also meet the clinical threshold for anti-obesity medication.<\/p>\n If you’ve been consistently following a reduced-calorie diet and exercising regularly for 6 months or more without losing at least 5% of your body weight, the evidence suggests lifestyle alone isn’t going to be sufficient. This isn’t failure. The biological deck is stacked against sustained weight loss through behavior change alone, as the Sumithran 2011 study and decades of weight loss research have shown.<\/p>\n The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend considering anti-obesity medications for:<\/p>\n These aren’t cosmetic drugs. They’re treating a disease that shortens life expectancy by an estimated 5-20 years depending on severity, according to a 2009 analysis in The Lancet by the Prospective Studies Collaboration.<\/p>\n Current guidelines from the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity (IFSO), updated jointly in 2022, recommend considering bariatric surgery for:<\/p>\n The previous threshold of BMI 40+ (or 35+ with comorbidities) was loosened based on strong evidence that surgery benefits patients at lower BMIs than previously thought.<\/p>\n For more on the decision framework, see our article on when to consider medication<\/a>.<\/p>\n Start with an honest assessment.<\/strong> Calculate your BMI (weight in pounds times 703, divided by height in inches squared). Note any weight-related health conditions you have. Think about what you’ve already tried and how it went.<\/p>\n A thorough evaluation should include:<\/p>\n A 5-10% reduction in body weight produces measurable health improvements. The DPP trial showed that 7% weight loss cut diabetes risk by 58%. You don’t need to reach a “normal” BMI to benefit. For someone at 280 pounds, losing 28 pounds (10%) can lower blood pressure, improve blood sugar control, reduce joint pain, and improve sleep quality.<\/p>\n Based on your evaluation, your provider can help determine the right combination of:<\/p>\n Whatever approach you choose, regular follow-up matters. Monthly check-ins during the first 3-6 months help catch side effects, adjust doses, troubleshoot adherence issues, and maintain momentum. After that, quarterly visits are typical.<\/p>\n Weight loss isn’t linear. You’ll have weeks where the scale doesn’t move, or moves up. That’s normal. The trend over months is what matters. Patients on GLP-1 medications typically see the most rapid weight loss in months 3-6, with a plateau around months 12-18.<\/p>\n\n
How Common Is Obesity in the United States?<\/h2>\n
What Causes Obesity?<\/h2>\n
Genetics<\/h3>\n
Hormones and Brain Signaling<\/h3>\n
Environment<\/h3>\n
Medications That Cause Weight Gain<\/h3>\n
Sleep and Stress<\/h3>\n
What Are the Health Risks of Obesity?<\/h2>\n
Type 2 Diabetes<\/h3>\n
Cardiovascular Disease<\/h3>\n
Cancer<\/h3>\n
Sleep Apnea<\/h3>\n
Mental Health<\/h3>\n
Joint Disease<\/h3>\n
What Are the Treatment Options for Obesity?<\/h2>\n
Lifestyle Modification<\/h3>\n
Pharmacotherapy (Anti-obesity Medications)<\/h3>\n
Bariatric Surgery<\/h3>\n
How Do GLP-1 Medications Work for Obesity?<\/h2>\n
Who Should Consider Obesity Treatment?<\/h2>\n
When Lifestyle Isn’t Enough<\/h3>\n
When to Consider Medication<\/h3>\n
\n
When to Consider Surgery<\/h3>\n
\n
How Do You Get Started with Obesity Treatment?<\/h2>\n
STEP 1: Get a Medical Evaluation<\/h3>\n
\n
STEP 2: Set Realistic Goals<\/h3>\n
STEP 3: Build a Treatment Plan<\/h3>\n
\n
STEP 4: Start Treatment and Follow Up<\/h3>\n
What Does Long-term Obesity Management Look Like?<\/h2>\n